Home / Stocks / Hikal Limited
HIKAL

Hikal Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹222.06

Change

-1.09 (-0.49%)

Open

₹222.0

Prev. Close

₹223.15

Day High

₹223.89

Day Low

₹217.21

Volume Analysis

Traded

110,989

Delivered

50,292

Delivery %

45.31%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (2.21%)
  • •Below-average fundamentals quality score (43/100)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹231.57 ₹227.73 ₹224.89 ₹221.05 ₹218.21 ₹214.37 ₹211.53
Fibonacci ₹227.73 ₹225.18 ₹223.6 ₹221.05 ₹218.5 ₹216.92 ₹214.37
Camarilla ₹223.9 ₹223.28 ₹222.67 ₹221.05 ₹221.45 ₹220.84 ₹220.22

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-2.14%

1 Week

-0.69%

1 Month

+5.36%

3 Months

+2.99%

6 Months

+8.14%

1 Year

-2.74%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-0.39%

Net margin -0.27% × asset turnover 0.73x × equity multiplier 1.98x

Company Overview

Sector

Healthcare

Market Cap

₹2,690 Cr

P/E (TTM)

37.8

ROE

2.21%

Book Value

₹95.8

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Hikal Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (86/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (2.21%); below-average fundamentals quality score (43/100). FII holding has been falling.

TopFund Score — Fundamentals Quality

43/100 — Weak

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

86

Growth

0

Valuation

47

Cash Flow

51

Corporate Governance

56

Momentum

63

Institutional Ownership

34

Business Quality

36

Risk & Volatility

26

Liquidity

30

From Screener.in

  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -0.09% over past five years.
  • −Company has a low return on equity of 5.16% over last 3 years.
  • −Dividend payout has been low at 8.37% of profits over last 3 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Earnings Call for the Quarter and half year ended September 30, 2026.

Pursuant to Regulation 30 and 47 of the SEBI LODR Regulations- Intimation of Newspaper Publication of Financial Results Q2 FY 27

Audio recording of Q2 and half-year earnings conference call held on November 3, 2026.

Result presentation for the quarter and half year ended September 30, 2026

Hikal reported Q2 FY27 results, signed a Europe agrochemical CDMO contract, and began Panoli production.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 435 448 514 407 453 448 552 380 319 494 519 403 434
Expenses + 377 383 420 349 378 376 429 355 311 412 414 366 389
Operating Profit 58 65 94 58 75 72 123 25 7 83 105 37 45
OPM % 13.23% 14.46% 18.36% 14.26% 16.54% 16.1% 22.34% 6.6% 2.26% 16.73% 20.29% 9.19% 10.34%
Other Income + 1 0 1 1 0 4 1 1 2 -35 -41 11 2
Interest 13 14 15 20 19 19 18 17 15 16 15 15 13
Depreciation 29 29 32 32 32 33 38 39 41 41 42 43 42
Profit before tax 17 22 47 7 25 24 68 -30 -47 -9 8 -10 -9
Tax % 25.44% 25.46% 28.33% 26.09% 26.21% 27.73% 26.5% -26.32% -25.74% -35.87% -73.49% -25.25% -28.24%
Net Profit + 13 16 34 5 18 17 50 -22 -35 -6 14 -7 -6
EPS in Rs 1 1 3 0 1 1 4 -2 -3 0 1 -1 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -22 -17 -6 5 4 0 7 -6 -30 10 -6 6 36

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 872 926 1,014 1,296 1,590 1,507 1,720 1,943 2,023 1,785 1,860 1,713 1,851
Expenses + 689 745 813 1,054 1,291 1,234 1,398 1,602 1,765 1,518 1,531 1,492 1,581
Operating Profit 182 181 201 242 298 273 323 341 258 267 328 220 270
OPM % 21.0% 20.0% 20.0% 19.0% 19.0% 18.0% 19.0% 18.0% 13.0% 15.0% 18.0% 13.0% 15.0%
Other Income + 2 2 -3 4 2 -12 5 5 5 2 5 -73 -63
Interest 60 62 48 49 58 52 36 31 48 56 75 62 58
Depreciation 64 67 69 86 93 82 85 96 109 118 134 164 168
Profit before tax 60 53 80 112 149 127 206 219 105 96 124 -78 -19
Tax % 32.0% 23.0% 16.0% 31.0% 31.0% 33.0% 36.0% 27.0% 26.0% 27.0% 27.0% -38.0% —
Net Profit + 40 41 68 77 103 84 133 160 78 70 91 -49 -5
EPS in Rs 3 3 5 6 8 7 11 13 6 6 7 -4 0
Dividend Payout % 20.0% 20.0% 15.0% 13.0% 14.0% 18.0% 19.0% 12.0% 19.0% 21.0% 19.0% -15.0% —
Sales growth 5 6 10 28 23 -5 14 13 4 -12 4 -8 9

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 516 547 589 653 732 792 909 1,043 1,109 1,163 1,238 1,174 1,157
Borrowings + 547 505 598 635 661 646 610 675 748 818 765 684 639
Other Liabilities + 212 206 177 237 268 306 370 470 504 482 502 483 521
Total Liabilities 1,292 1,275 1,379 1,542 1,686 1,768 1,913 2,213 2,385 2,487 2,529 2,365 2,341
Fixed Assets + 639 623 668 634 713 735 713 879 948 1,071 1,364 1,333 1,319
CWIP 62 66 63 118 79 161 254 295 412 414 121 94 94
Investments 3 3 4 3 1 1 1 11 5 5 10 10 10
Other Assets + 588 583 645 788 893 871 946 1,028 1,020 997 1,034 928 918
Total Assets 1,292 1,275 1,379 1,542 1,686 1,768 1,913 2,213 2,385 2,487 2,529 2,365 2,341
Equity Capital 16 16 16 16 25 25 25 25 25 25 25 25 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 102 186 163 139 186 285 229 294 315 187 280 302
Cash from Investing Activity + -43 -64 -102 -110 -125 -164 -156 -284 -292 -174 -136 -145
Cash from Financing Activity + -69 -124 -63 -25 -55 -101 -97 -6 -8 -27 -144 -160
Net Cash Flow -10 -2 -2 4 6 20 -24 4 15 -14 0 -3
Free Cash Flow 54 127 58 33 57 127 71 21 13 -17 144 154
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 63 110 91 68 73 113 85 107 134 81 94 144

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 68.85% → 68.85%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 21.85% 21.06% 21.32% 20.79% 21.61% 21.65% 21.76% 21.75% 21.78% 22.51% 22.92% 24.57%
Promoters 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85%
FII 6.14% 6.55% 6.66% 6.78% 6.06% 5.7% 5.35% 4.23% 2.31% 1.44% 0.98% 1.28%
DII 3.15% 3.53% 3.17% 3.58% 3.48% 3.8% 4.03% 5.15% 7.05% 7.2% 7.23% 5.31%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Hikal Limited (this stock) 2,690 37.8 2.28 2.21%
Fredun Pharmaceuticals L 2,548 48.1 7.59 15.6%
Ind Swift Laboratories Lt 2,881 31.4 1.95 4.02%
Advanced Enzyme Tech Ltd 3,102 19.1 1.9 10.5%
Vimta Labs Limited 2,230 36.7 6.46 13.5%
Sai Parenterals Limited 2,189 87.8 4.42 4.88%
Dishman Carbo Amcis Ltd 2,183 151.0 0.33 1.58%

Which Mutual Funds Hold Hikal Limited?

Frequently Asked Questions about Hikal Limited

Community Sentiment

What are other investors saying about Hikal Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.